Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
2qa8kbU8vy5z3pDy
